Corvus Pharmaceuticals, Inc. (FRA:C17)

Market Cap	1.15B +533.0%
Revenue (ttm)	n/a
Net Income	-13.02M
EPS	-0.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2
Open	13.62
Previous Close	14.77
Day's Range	13.62 - 13.62
52-Week Range	2.84 - 21.70
Beta	n/a
RSI	59.41
Earnings Date	May 7, 2026

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferat...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 37
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C17

Financial Performance

Financial numbers in USD